ity analysis and principled decision making based on the results from sensitivity analyses, (2) analysis of data where the missingness pattern is nonmonotone, (3) sample size calculations in the presence of missing data, (4) design of clinical trials, in particular plans for follow-up after treatment discontinuation (degree of sampling, how many attempts are made, etc.), and (5) doable robust methods, to more clearly understand their strengths and vulnerabilities in practical settings. The development of software that supports coherent missing data analyses is also a high priority.

The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement